Los Angeles Capital Management LLC Purchases 1,223,895 Shares of Gilead Sciences, Inc. $GILD

Los Angeles Capital Management LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 46.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,845,379 shares of the biopharmaceutical company’s stock after buying an additional 1,223,895 shares during the quarter. Gilead Sciences makes up 1.4% of Los Angeles Capital Management LLC’s holdings, making the stock its 11th largest holding. Los Angeles Capital Management LLC owned about 0.31% of Gilead Sciences worth $426,837,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in GILD. Vanguard Group Inc. increased its position in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Geode Capital Management LLC increased its holdings in Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after buying an additional 727,515 shares during the period. Norges Bank bought a new position in Gilead Sciences in the second quarter worth approximately $2,150,268,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after buying an additional 1,520,809 shares during the period. Finally, Invesco Ltd. boosted its position in Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the transaction, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 136,257 shares of company stock worth $16,855,192. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 1.4%

Shares of Gilead Sciences stock opened at $123.18 on Wednesday. The firm’s 50 day simple moving average is $122.97 and its two-hundred day simple moving average is $116.89. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $152.83 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 0.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is currently 48.99%.

Wall Street Analyst Weigh In

GILD has been the subject of several recent research reports. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Daiwa Capital Markets boosted their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Wolfe Research restated an “outperform” rating and issued a $150.00 price target on shares of Gilead Sciences in a report on Monday, December 15th. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Finally, UBS Group upgraded shares of Gilead Sciences to a “hold” rating in a research note on Thursday, December 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.68.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.